Current filters:


1 to 9 of 16 results

Clinigen to provide first access to anti-bacterial Vibativ in Europe

Clinigen to provide first access to anti-bacterial Vibativ in Europe


UK-based Clinigen Group has announced the initiation of an early access program to provide the anti-bacterial…

Antibiotics and Infectious diseasesClinigen GroupEuropeLicensingPharmaceuticalProductionUKVibativ

Theravance reintroduces Vibativ in USA


US drug developer Theravance (Nasdaq: THRX) says it has commenced shipments of Vibativ (telavancin) into…

Antibiotics and Infectious diseasesAstellas PharmaMarkets & MarketingNorth AmericaPharmaceuticalProductionTheravanceVibativ

Hikma licenses Vibativ from Theravance for MENA region


Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) says it has signed an exclusive commercialization…

Antibiotics and Infectious diseasesHikma PharmaceuticalsLicensingPharmaceuticalRest of the WorldTheravanceVibativ

Mixed FDA panel vote for Theravance's Vibativ for nosocomial pneumonia


US drug developer Theravance (Nasdaq: THRX) saw its shares rise more than 5% $22.48 by close of trading…

Antibiotics and Infectious diseasesPharmaceuticalRegulationTheravanceVibativ

Astellas pulls out of deal with Theravance


Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA


The European Commission has granted marketing authorization for Japanese drug major Astellas’ (TYO:…

Antibiotics and Infectious diseasesAstellas PharmaEuropePharmaceuticalRegulationTheravanceVibativ

1 to 9 of 16 results

Back to top